Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 2/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CD69 | Q07108 | 5/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | PTPRB | P23467 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | ELANE | P08246 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2059355 | 0.86 | CSNK2A2 (0.49) | MCL1KMT2AMEN1CD69HPGD | |
| SCHEMBL11570516 | 0.82 | KDM4E (0.55) | MCL1KMT2AHPGDKDM4EPKM | |
| SCHEMBL2059557 | 0.82 | AGBL2 (0.46) | THRATHRBMCL1KMT2ACD69 | |
| SCHEMBL3201351 | 0.82 | KMT2A (0.55) | MCL1KMT2AMEN1CD69HPGD | |
| SCHEMBL8240454 | 0.82 | MCL1 (0.45) | THRATHRBMCL1KMT2ACD69 | |
| SCHEMBL14931907 | 0.82 | MCL1 (0.45) | THRATHRBMCL1KMT2ACD69 | |
| SCHEMBL11332162 | 0.81 | HSD17B10 (0.46) | THRATHRBMCL1KMT2AMEN1 | |
| SCHEMBL3681218 | 0.81 | HSP90AB1 (0.47) | KMT2AMEN1HSD17B10ALDH1A1POLB | |
| SCHEMBL6165860 | 0.81 | HSD17B10 (0.56) | THRATHRBMCL1KMT2ACD69 | |
| SCHEMBL13534917 | 0.79 | ALDH1A1 (0.57) | THRATHRBMCL1KMT2ACD69 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968707-B2 | Reacting an amino, hydroxy substituted amide with a heterocyclic substituted carboxylic acid to produce (2S,3S,5S)-2-(2,6-Dimethylphenoxyacetyl) amino-3-hydroxy-5-[2S-1-imidazolidin-2-onyl)-3-methyl-butanoyl] amino-1,6-diphenylhexane; inhibitors of HIV infection | ABBOTT LABORATORIES (US) | 2011-06-28 | — | — | US | disclosed |
| US-20080139811-A1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | ABBVIE INC. | 2008-06-12 | — | — | US | disclosed |
| US-7279582-B2 | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 2007-10-09 | — | — | US | disclosed |
| US-20030100755-A1 | Retroviral protease inhibiting compounds | ABBVIE INC. | 2003-05-29 | — | — | US | disclosed |
| EP-1295874-A2 | Retroviral protease inhibiting compounds | Abbott Laboratories (US) | 2003-03-26 | — | — | EP | disclosed |
| US-6472529-B2 | VIRICIDES | ABBOTT LABORATORIES | 2002-10-29 | — | — | US | disclosed |
| EP-0882024-B1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | ABBOTT LAB (US) | 2002-02-06 | — | — | EP | disclosed |
| US-20020004503-A1 | Retroviral protease inhibiting compounds | ABBVIE INC. | 2002-01-10 | — | — | US | disclosed |
| EP-1170289-A2 | Retroviral protease inhibiting compounds | Abbott Laboratories (US) | 2002-01-09 | — | — | EP | disclosed |
| US-6313296-B1 | 2-PYRROLIDINONE-1-ACETIC ACID DERIVATIVES; VIRICIDES FOR HUMAN IMMUNODEFICIENCY VIRUS (HIV); ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) TREATMENT | ABBOTT LABORATORIES | 2001-11-06 | — | — | US | disclosed |
| US-6284767-B1 | AIDS; MIXTURE WITH ENZYME INHIBITOR | ABBOTT LABORATORIES | 2001-09-04 | — | — | US | disclosed |
| US-5914332-A | NOVEL COMPOUNDS FOR USE AS HIV PROTEASE INHIBITORS IN TREATING HIV AND AIDS | ABBOTT LABORATORIES (US) | 1999-06-22 | — | — | US | disclosed |
| EP-0882024-A1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | Abbott Laboratories (US) | 1998-12-09 | — | — | EP | disclosed |
| EP-0876353-A1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | Abbott Laboratories (US) | 1998-11-11 | — | — | EP | disclosed |
| WO-1997021685-A1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 1997-06-19 | — | — | WO | disclosed |
| WO-1997021683-A1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 1997-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139811-A1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | SERPINB1, PREP, DNPEP | THRA 4692/4885THRB 4276/4885MCL1 246/4885 |
| US-20030100755-A1 | Retroviral protease inhibiting compounds | SERPINB1, PREP, TMPRSS15 | THRA 4718/4885THRB 4481/4885MCL1 167/4885 |
| US-20020004503-A1 | Retroviral protease inhibiting compounds | SERPINB1, PREP, TMPRSS15 | THRA 4718/4885THRB 4481/4885MCL1 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.